Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Renal Cell 7Sarcoma 5Melanoma 5Lymphoma, Non-Hodgkin 5Prostatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Kidney Neoplasms 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Liver Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1

Interventions

Cytarabine 8Idarubicin 4Peripheral Blood Stem Cell Transplantation 3Filgrastim 2Etoposide 2Clofarabine 2tipifarnib 1temsirolimus 1sargramostim 1laromustine 1eltrombopag 1alvocidib 1aldesleukin 1Whole-Body Irradiation 1Radiotherapy 1Proto-Oncogene Proteins c-kit 1Polymerase Chain Reaction 1Mitoxantrone 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Gene Expression Profiling 1Gemtuzumab 1Flow Cytometry 1Daunorubicin 1Cyclosporine 1Cyclophosphamide 1Cilengitide 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Eosinophilic, Acute × temsirolimus × Clear all
NCT00775593 2017-11-09

AML1107

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed
60 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡